ClinicalTrials.gg
Not yet recruitingNCT07820930ReDEFINE-AFUpdated Oct 23, 2026

A Global Randomized Trial Evaluating the FARAFLEX™ Mapping and Pulsed Field Ablation System With Electrographic Flow Mapping in Patients Undergoing Repeat Ablation for Atrial Fibrillation

An interventional study of FARAFLEX Mapping and Pulsed Field Ablation System in Atrial Fibrillation (AF), Persistent Atrial Fibrillation (PersAF) and Paroxysmal Atrial Fibrillation (PAF), sponsored by Boston Scientific Corporation. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Boston Scientific Corporation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
650
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 73 studies in Atrial Fibrillation by Boston Scientific Corporation — 8 open to participants now, 20 under way, none of them phase 3. Atrial Fibrillation · Boston Scientific Corporation.

Planned enrollment
9th of 51
650 · median 200
Started
2026
with 4 others
No phase
45 of 73
8 open now
Primary completion
2029-07
later than 19 of 19 live
Registered
72nd of 73
by date

Among the 73 studies in Atrial Fibrillation by Boston Scientific Corporation, this one is the 9th largest by planned enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2026, is one of 45 with no phase, reaches primary completion later than 19 of the 19 other live ones, and was the 72nd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 963 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 73 studies in Atrial Fibrillation by Boston Scientific Corporation are open now, in 11 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 609 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Atrial Fibrillation by Boston Scientific Corporation, or all of them as a file.
02

Study summary

The goal of the ReDEFINE-AF Clinical Study is to evaluate the safety and effectiveness of the FARAFLEX™ Mapping and Pulsed Field Ablation System with electrographic flow mapping in subjects undergoing repeat ablation for atrial fibrillation (AF).

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Persistent Atrial Fibrillation (PersAF)
  • Paroxysmal Atrial Fibrillation (PAF)

Browse trials for

Keywords

  • Pulsed Field Ablation
  • Electrographic Flow Mapping
  • FARAFLEX
  • OptiMap
  • Catheter Ablation
  • EGF
  • Repeat Ablation
  • Pulmonary Vein Isolation
  • Posterior Wall Ablation
  • ICM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years old, or older if required by local law.
  2. Subjects with symptomatic atrial fibrillation who have documented Persistent Atrial Fibrillation (PersAD) or Paroxysmal Atrial Fibrillation (PAF) with at least one documented symptomatic AF episode lasting at least 24 hours.

    AND Undergone one failed endocardial atrial fibrillation ablation procedure OR undergone no more than two prior endocardial atrial fibrillation ablation procedures that were both limited to PV and/or PW ablation.

  3. Willing and capable of providing .
  4. Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical center.
  5. Willing to receive a LUX-Dx insertable cardiac monitor (ICM) during the study or already has a LUX-Dx ICM that was inserted within 6 months prior to consent, and willing to comply with the LUX-Dx Latitude Clarity transmission instructions.

Exclusion criteria

Exclusion Criteria:

  1. Any of the following atrial conditions:

    1. Left atrial anteroposterior (LA) diameter ≥ 6.5 cm, or if LA diameter is not available, non-indexed LA volume >100 mL.
    2. Current atrial myxoma.
    3. Current left atrial thrombus.
    4. Any PV abnormality, stenosis, or stenting. Common and middle PVs are admissible.
  2. Any of the following cardiovascular conditions:

    1. History of sustained ventricular tachycardia or any ventricular fibrillation.
    2. Severe right ventricular dysfunction with documented echocardiography and/or hemodynamic data.
    3. Atrial Fibrillation (AF) that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible/non-cardiac causes.
    4. Presence of any of the following:

      • Current or anticipated pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy device.
      • Implantable loop recorder other than a LUX-Dx device
      • Interatrial baffle, atrial septal defect or patent foramen ovale closure device or patch
      • Left Atrial Appendage Closure or Occlusion Device
    5. Presence of any of the following:

      • Any cardiac valve prosthesis, ring, repair, or clip.
      • Mitral valve stenosis: moderate or greater.
      • Aortic stenosis: moderate or greater.
      • Severe mitral regurgitation.
      • Severe tricuspid regurgitation.
    6. Hypertrophic or amyloid cardiomyopathy.
    7. Any IVC filter, known inability to obtain vascular access, or other to femoral access.
    8. Awaiting cardiac transplantation or other planned cardiac surgery within the next 12 months.
  3. Any of the following conditions documented during eligibility assessment or Baseline Assessment, as applicable:

    1. Heart failure associated with Class III or IV, as documented during eligibility assessment or Baseline Assessment.
    2. Most recent documented \<40% within the previous 12 months.
    3. (BMI) >45.0 kg/m², as documented during eligibility assessment or Baseline Assessment.
    4. Known coagulopathy or bleeding disorder.
    5. Contraindication to, or unwillingness to use, systemic anticoagulation or acceptable alternatives pre-, intra-, and post-procedure to achieve adequate anticoagulation.
    6. Women who are confirmed to be pregnant or lactating at the time of the ablation procedure.
    7. Severe lung disease, including but not limited to severe pulmonary hypertension, involving abnormal blood gases or requiring supplemental oxygen.
    8. Active other than squamous cell carcinoma.
    9. gastrointestinal problems involving the esophagus or stomach, including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis, or active gastroduodenal ulceration.
    10. Known active systemic infection.
    11. Predicted of less than one year per Investigator medical judgment.
    12. Subjects who are currently enrolled in another study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry or a purely observational registry with no associated treatments.
    13. Required use of phosphodiesterase inhibitors within 24 hours of the ablation procedure.
    14. Known allergic drug reaction to nitroglycerin, excluding hypotension.
    15. Unwillingness to receive, or unable to tolerate, a subcutaneous, chronically inserted LUX-Dx ICM device.
    16. Presence of an active spinal cord stimulator.
  4. Any of the following congenital conditions:

    1. Congenital heart disease with any clinically significant residual anatomic or conduction abnormality.
    2. History of known congenital methemoglobinemia.
    3. History of known G6PD deficiency.
  5. Any of the following conditions in the medical history:

    1. Solid organ or hematologic transplant, or currently being evaluated for a transplant.
    2. Any prior history or current evidence of hemi-diaphragmatic paralysis or paresis.
    3. Any documented history of Prinzmetal angina or severe non-revascularizable coronary disease.
    4. Renal insufficiency if an estimated (eGFR) is \<30 mL/min/1.73 m², or any history of renal dialysis or renal transplant.
    5. Any other general health condition that, in the Investigator's medical opinion, would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.
  6. Any of the following events within 90 days prior of the consent date:

    1. Myocardial infarction, unstable angina, or coronary intervention.
    2. Any cardiac surgery.
    3. Heart failure hospitalization.
    4. Pericarditis or symptomatic pericardial effusion.
    5. Gastrointestinal bleeding.
    6. Stroke, , or intracranial bleeding.
    7. Any active non-neurologic thrombus and/or thromboembolic event.
    8. Carotid stenting or endarterectomy.
    9. Uncontrolled diabetes mellitus or a recorded >8.0%.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
650 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    Subjects will undergo EGF mapping using the OptiMap™ Catheter and System, followed by ablation of eligible EGF-identified extra-pulmonary vein sources using the FARAFLEX™ Mapping and PFA System.

    Device: FARAFLEX Mapping and Pulsed Field Ablation System

  • Active comparator
    Control Arm

    Subjects will undergo EGF mapping using the OptiMap™ Catheter and System. For Control Arm subjects who have not previously undergone posterior wall ablation/isolation and who do not have documented durable posterior wall isolation, protocol-defined de novo posterior wall ablation will be performed using the FARAFLEX™ Mapping and PFA System.

    Device: FARAFLEX Mapping and Pulsed Field Ablation System

Interventions

  • DeviceFARAFLEX Mapping and Pulsed Field Ablation System

    Catheter used for electrophysiological mapping of cardiac structures and the treatment of paroxysmal or persistent atrial fibrillation.

06

What researchers measure

Primary outcomes

  1. The Primary Effectiveness Endpoint (PEE) is the Proportion of Randomized Subjects in the Main Study Cohort achieving Treatment Success through the Day 365 Assessment.

    The Primary Effectiveness Endpoint analysis will compare Treatment Success between the Treatment Arm and the Control Arm in randomized subjects in the Main Study Cohort.

    Time frame: Day 180 through Day 365 Assessment

Secondary outcomes

  1. The Secondary Safety Endpoint is the rate of protocol-defined device- or procedure-related Composite Serious Adverse Events (CSAE).

    The secondary safety endpoint will be evaluated in Randomized Treatment Arm subjects and will not contribute to study success criteria.

    Time frame: Day 0 through Day 60

07

Study locations

No study locations are listed for this record.

08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2029, 32 months later.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 32 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2026
First posted
Sep 15, 2026
StartEst.
Nov 2026
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2031
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: arm descriptions and verification date
2 updates, last Oct 23, 2026
Show all 2 updates
  1. Oct 23, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 28, 2026
    Minor edits only
    + 1 other change: arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07820930
Responsible party
Sponsor
First posted
Sep 15, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jul 2029 (estimated)
Completion
Jul 2031 (estimated)
Last update
Oct 23, 2026

Study contacts

Eliza Lawrence
Contact
Eliza.Lawrence@bsci.com
(650) 215-1267
Monika Bushko
Contact
monika.bushko@bsci.com
(617)218-3963

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion